To reduce reagent complexity and improve delivery potential, inhibition of MMEJ could also be achieved by a small molecule inhibitor of Polθ89 rather than a siRNA mix targeting POLQ. It is promising that small molecule inhibitors of both the NHEJ and the MMEJ pathways are already in clinical trials for the treatment of cancers90–93 and that in contrast to state-of-the-art cancer treatment using chemotherapy, which introduces DSBs in any dividing cell, SNIPE would selectively induce DSBs in cancer cells. This evidence concerns the gene POLQ and cancer.